Correlate of immune protection against HSV-1 genital disease in vaccinated women. - Wikidata - wikimedia - TriplyDB

Correlate of immune protection against HSV-1 genital disease in vaccinated women.

Correlate of immune protection against HSV-1 genital disease in vaccinated women.

http://www.wikidata.org/entity/Q37604473

about

Understanding natural herpes simplex virus immunity to inform next-generation vaccine design The herpevac trial for women: Sequence analysis of glycoproteins from viruses obtained from infected subjects.Global sensing of the antigenic structure of herpes simplex virus gD using high-throughput array-based SPR imaging.Repertoire of epitopes recognized by serum IgG from humans vaccinated with herpes simplex virus 2 glycoprotein D Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates An HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs.Anti-glycoprotein g antibodies of herpes simplex virus 2 contribute to complete protection after vaccination in mice and induce antibody-dependent cellular cytotoxicity and complement-mediated cytolysis Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans Bovine herpesvirus glycoprotein D: a review of its structural characteristics and applications in vaccinology Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease.Evasion of early antiviral responses by herpes simplex viruses.The Current State of Vaccine Development for Ocular HSV-1 Infection Seroprevalence of Herpes Simplex Virus Type 1 and 2 in Taiwan and Risk Factor Analysis, 2007.Higher Throughput Quantification of Neutralizing Antibody to Herpes Simplex Viruses.Global Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins.A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific.Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection.Nasal Immunization Confers High Avidity Neutralizing Antibody Response and Immunity to Primary and Recurrent Genital Herpes in Guinea Pigs.Future prospects for new vaccines against sexually transmitted infections.Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.The Neonatal Fc Receptor and Complement Fixation Facilitate Prophylactic Vaccine-Mediated Humoral Protection against Viral Infection in the Ocular Mucosa.Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.Reply to "Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?"Dual-strain genital herpes simplex virus type 2 (HSV-2) infection in the US, Peru, and 8 countries in sub-Saharan Africa: A nested cross-sectional viral genotyping study.Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged ≥50 Years.Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.A new era in cytomegalovirus vaccinology: considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection

P2860

Q26741484-F40B0056-25D1-4782-96E9-776F685A36DD Q33610941-3184AEF8-0713-4FFA-A229-BC8832FFE3A3 Q33834821-C3EE076A-C283-45A4-AFAD-68430B006363 Q33900262-38352C1B-6F23-4AA0-9318-1E0CC0F3CCF5 Q34057952-8B6F0183-2682-438F-81EE-6695A7D9E6D5 Q34229689-8EAF2757-2498-40DF-ADFB-1A8ED149B930 Q34414463-BBB11CF2-5BB1-4A70-86E6-3F92EF023BE8 Q34520389-3B0E6E17-CDBA-423C-BE84-5530F004C8C7 Q34537743-A0C8963F-8743-4081-9AD4-EBCC152D2FED Q34549656-021C62A5-D30D-4934-A120-E117922EDDB9 Q34580831-C9147F34-2A5D-4CA5-9C8E-7E675DE872D9 Q34593833-0E925705-46F9-4AD7-AFF3-7457E06D2E55 Q34611897-10D32E14-2858-46CB-95E7-C3FC5391E93A Q35156674-DFD4B4DD-3D7A-4590-B739-F736F34DD14E Q35414669-BE8EAAEF-E659-4910-A598-773ED4E9DF6F Q35606611-89312AE6-F508-459B-924F-9EA1EC3BF052 Q35739600-11B44DB8-4929-4C2B-9754-5203DAC1FA99 Q35866976-36F05357-4FF7-429D-9777-54C1EB20F476 Q35914319-E4BEFCA8-3E07-4FB9-BC95-1702F0F659D5 Q35914367-9861EA38-F155-40EB-ADEA-8025D8DCCACA Q35973512-6D35C6AD-0222-4071-B073-3A28F7842325 Q36080869-612B12F2-3BE3-40CD-BCC0-E354A5F99BE6 Q36630996-EAB82F9E-4716-48C2-88F6-6FFAC05166D4 Q36824210-90625A7A-CAC5-4CCA-BB42-5884CD9D7832 Q36846035-E1D00857-2832-4938-A7F3-12EC31A4ABDA Q37531713-86E6C2C9-51F1-47CC-93F5-6A73495B30D8 Q37665012-F25AFF20-DF53-4A8C-835D-768596AC6B12 Q38241377-EF9E8CDC-38C4-492B-ABA3-B831043D532A Q38650844-17581A3A-A67A-4425-8FF8-C05D55CEB14E Q41928445-340CCB7F-A4F7-4BD2-8DD4-4C2FC2AC6A3C Q45324844-0A06C6C3-795B-484C-8A8D-9840F7EBBEB0 Q47184537-283FCB4C-7219-4D66-B710-A6C5E52FF51E Q52727148-09EEBD2D-E084-4563-9D02-C5086802C14D Q55406946-E404E96D-50F9-41C8-B6CF-1506FCA492F9 Q57072187-E6AB0BD5-2A50-49FE-BA22-7FADC635D9E6

P2860

Correlate of immune protection against HSV-1 genital disease in vaccinated women.

http://www.wikidata.org/entity/Q37604473

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Correlate of immune protection against HSV-1 genital disease in vaccinated women.

@en

Correlate of immune protection against HSV-1 genital disease in vaccinated women.

@nl

type

label

Correlate of immune protection against HSV-1 genital disease in vaccinated women.

@en

Correlate of immune protection against HSV-1 genital disease in vaccinated women.

@nl

prefLabel

Correlate of immune protection against HSV-1 genital disease in vaccinated women.

@en

Correlate of immune protection against HSV-1 genital disease in vaccinated women.

@nl

P1433

Q37604473-8C0F1A00-4A1C-4F9D-B1D3-C59EF714E4CD

P1476

Q37604473-16D7E2B0-CAA6-4317-A9CF-8A54025FE480

P2093

Q37604473-11A39D5A-1D10-4BB4-B151-CDA0D224E0EB

Q37604473-24AFBABF-E0F7-46C3-9AFD-98858D55B600

Q37604473-3B0EF74C-8E82-417A-922F-282215C661EA

Q37604473-623F75AE-B9CA-441A-8891-AB4392C56537

Q37604473-6B024CE8-E89B-4390-82ED-5B895FF5EE7D

Q37604473-BD6B9AC4-C157-45A8-9EBC-9DC938BE8C5F

Q37604473-D6CF51E9-6A8E-4DA8-83AA-FC57F6B8929E

P2860

Q37604473-23ABA680-2F87-469A-9F6F-B67ECA95EABC

Q37604473-28B427FD-C682-44BE-8C27-74628683B625

Q37604473-56221F7D-EDFC-4D3E-93CD-7F20D30A5CA9

Q37604473-91011331-B16C-483A-B04E-5631F7DDAE4A

Q37604473-B00ED7D7-B55A-4042-B3AA-2D17BB48CD3A

Q37604473-BA73D673-AE01-4558-9504-E30A1F67FC58

Q37604473-C63CB341-7BD2-4F5C-A5A8-9A6BD0FDC92E

Q37604473-EAA4F102-3402-4B70-BA35-D3393E9C7469

P304

Q37604473-23FFFEE8-86DA-42A5-8CB6-00F8CB444865

P31

Q37604473-C0AF64F9-5211-4DDB-8722-310E0CD2233E

P356

Q37604473-355A7006-FE78-4DD1-A7DB-DE1827A62BD0

P407

Q37604473-14B343E0-ABF9-4B3C-8D57-330360B99372

P433

Q37604473-9618D529-5140-4FDF-A64D-A4F9EA3F9D3E

P478

Q37604473-C68E1543-BBAF-4A81-9277-BC6DBF6A48B9

P577

Q37604473-EEE8818D-80A7-4E0F-83A4-19629A7887CF

P698

Q37604473-642DFC87-D10B-405A-8549-9B782325057E

P932

Q37604473-A3B0F2F8-1796-484B-9339-CACD37A6E756

P356

P1433

The Journal of Infectious Diseases

P1476

Correlate of immune protection against HSV-1 genital disease in vaccinated women.

@en

P2093

Abbie R Bellamy

http://www.w3.org/2001/XMLSchema#string

Carolyn D Deal

http://www.w3.org/2001/XMLSchema#string

David I Bernstein

http://www.w3.org/2001/XMLSchema#string

Marian Ewell

http://www.w3.org/2001/XMLSchema#string

Robbert van der Most

http://www.w3.org/2001/XMLSchema#string

Robert B Belshe

http://www.w3.org/2001/XMLSchema#string

Thomas C Heineman

http://www.w3.org/2001/XMLSchema#string

P2860

Immunofluorescence analysis of T-cell responses in health and disease.

Efficacy results of a trial of a herpes simplex vaccine.

Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women

Cervical antibody responses to a herpes simplex virus type 2 glycoprotein subunit vaccine.

Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2.

Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine.

A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults.

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

P304

828-836

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIT651

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

209

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24285844

http://www.w3.org/2001/XMLSchema#string

P932

3935479

http://www.w3.org/2001/XMLSchema#string